Sunil Healthcare Limited share price
Sunil Healthcare Limited engages in the manufacture and sale of empty hard gelatin, hydroxypropyl methylcellulose (HPMC), and pullulan capsules shells in India and internationally. It offers EHG, BSE/TSE free, pearl, liquid fill, preservative free, stick free, flavored, SLS free, natural color, non-AZO, gelatin, HPMC/vegetable, and pullulan capsules. The company also provides ayurvedic products, such as haldi, ginger, vasaka, trifala, guduchi, salaki, punarvana, shatavari, hadjod, hingwastak, mulethi, arjuna, ashwagandha, and guggul extracts. The company offers its products under the SUNLOC brand name. Sunil Healthcare Limited was incorporated in 1973 and is based in New Delhi, India.Read more
- Market Cap₹ 72 Cr.
- Current Price₹ 69.99
- High / Low₹ 82 / 65
- Stock P/E20.2
- Book Value₹ 68
- Dividend Yield0.00 %
- ROCE7.3 %
- ROE5.90 %
- Face Value—
More figures (10)
- EPS (TTM)₹ 3.47
- Price / Book1.03
- OPM9.5 %
- Debt / Equity0.78
- Sales growth (3Y)-7.5 %
- Profit growth (3Y)-15.7 %
- Promoter holding88.2 %
- EV / EBITDA9.9
- Beta-0.05
- All-time high₹ 82
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| SUNLOC | -4.76% | — | — | — | — | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Sunil Healthcare Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹72 crore.
- It trades at 20.2 times its last 12 months' earnings and 1.0 times book value.
- Revenue grew -7.5% a year over the last 3 years, profit -15.7% a year.
- Return on equity was 5.9% and return on capital employed 7.3% in the latest year.
- Debt was 0.78 times shareholders' equity.
- The share price is 14.7% below its 52-week high.
- Promoters and insiders hold about 88.2%; institutions about 0.0%.
Pros
AINo standout strengths in the reported figures.
Cons
AI- Return on equity has been low: 0.3% on average over the last 3 years.
- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Sunil Healthcare Limited
Sunil Healthcare Limited engages in the manufacture and sale of empty hard gelatin, hydroxypropyl methylcellulose (HPMC), and pullulan capsules shells in India and internationally. It offers EHG, BSE/TSE free, pearl, liquid fill, preservative free, stick free, flavored, SLS free, natural color, non-AZO, gelatin, HPMC/vegetable, and pullulan capsules. The company also provides ayurvedic products, such as haldi, ginger, vasaka, trifala, guduchi, salaki, punarvana, shatavari, hadjod, hingwastak, mulethi, arjuna, ashwagandha, and guggul extracts. The company offers its products under the SUNLOC brand name. Sunil Healthcare Limited was incorporated in 1973 and is based in New Delhi, India.
- Employees
- 158
- Head office
- New Delhi
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sunil Healthcare | 69.99 | 20.2 | 72 | 0.00 | 0 | -48.99 | 19 | -16.15 | 7.3 | 5.9 | 1.03 | 9.5 | 0.78 | 88.18 | 87 | -7.5 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,835 | 54.57 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,753 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 789 | -35.42 | 7,077 | 7.26 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 27,712 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 568 | 35.00 | 4,031 | 30.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 35 Co. | 1,712.85 | 33.0 | 31,766 | 0.33 | 679 | 8.79 | 5,956 | 18.81 | 14.6 | 16.8 | 4.93 | 17.5 | 0.30 | 55.20 | 20,499 | 13.4 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
| ₹ Cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 23 | 24 | 22 | 20 | 19 |
| Operating Profit | 2 | 2 | 2 | 0 | 1 |
| Profit before tax | 1 | 1 | 1 | -1 | 0 |
| Net Profit | 1 | 1 | 1 | 2 | 0 |
| EPS in Rs | 0.89 | 0.97 | 0.57 | 1.48 | 0.45 |
Profit & Loss
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 110 | 90 | 83 | 87 |
| Operating Profit | 12 | -1 | 7 | 8 |
| Interest | 3 | 5 | 6 | 5 |
| Depreciation | 7 | 6 | 6 | 6 |
| Profit before tax | 9 | -3 | -1 | 2 |
| Net Profit | 7 | -2 | -1 | 4 |
| EPS in Rs | 6.52 | -1.74 | -1.38 | 3.91 |
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 |
| Reserves | 46 | 58 | 57 | 59 |
| 36 | 65 | 67 | 54 | |
| Long term borrowings | 8 | 19 | 18 | 14 |
| Short term borrowings | 26 | 46 | 49 | 40 |
| 29 | 25 | 28 | 41 | |
| Trade payables | 15 | 6 | 9 | 16 |
| Current liabilities | 45 | 57 | 63 | 66 |
| Total Liabilities | 121 | 158 | 162 | 165 |
| 70 | 93 | 94 | 88 | |
| Gross block | 108 | 134 | 142 | 139 |
| Accumulated depreciation | 37 | 41 | 48 | 51 |
| Goodwill & intangibles | 0 | 0 | 0 | 0 |
| CWIP | 0 | 6 | 0 | 2 |
| 50 | 59 | 67 | 75 | |
| Inventories | 14 | 14 | 18 | 19 |
| Trade receivables | 28 | 41 | 42 | 45 |
| Cash & equivalents | 1 | 0 | 0 | 0 |
| Current assets | 48 | 62 | 65 | 74 |
| Total Assets | 121 | 158 | 162 | 165 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 7 | -15 | 12 | 22 | |
| Profit for the year | 7 | -2 | -1 | 4 |
| Working capital changes | -8 | -23 | -0 | 6 |
| Direct taxes paid | -1 | -1 | 0 | -0 |
| -3 | -10 | -8 | -3 | |
| Fixed assets purchased | -4 | -10 | -9 | -4 |
| Fixed assets sold | 1 | 0 | 0 | 0 |
| Investments purchased | -1 | -0 | -0 | |
| Investments sold | 1 | 1 | 1 | |
| -4 | 25 | -4 | -19 | |
| Proceeds from borrowings | 4 | 36 | 8 | 1 |
| Repayment of borrowings | -6 | -5 | -6 | -14 |
| Interest paid | -4 | -6 | -6 | -6 |
| Net Cash Flow | 0 | -1 | -0 | 0 |
| Free Cash Flow | 3 | -26 | 2 | 19 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROE | 11.9% | -2.9% | -2.1% | 5.9% |
| ROCE | 17.0% | 2.2% | 4.5% | 7.3% |
| Operating margin | 11.1% | -1.4% | 8.0% | 9.5% |
| Net margin | 6.0% | -2.0% | -1.7% | 4.6% |
| Debt / equity | 0.64 | 0.95 | 1.00 | 0.78 |
| Current ratio | 1.06 | 1.09 | 1.04 | 1.11 |
| Debtor days | 94 | 164 | 182 | 188 |
| Inventory days | 97 | 102 | 162 | 191 |
| Days payable | 105 | 44 | 82 | 163 |
| Cash conversion cycle | 86 | 222 | 262 | 216 |
| Working capital days | 9 | 21 | 11 | 31 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
- Promoters & insiders 88.18%
- Institutions (FII, DII, funds) 0.00%
- Public & others 11.82%
Key dates
- Ex-dividend date
- 1 Jan 1970
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
No recent announcements.
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Sunil Healthcare Limited
What is the share price of Sunil Healthcare Limited today?
What is the market cap of Sunil Healthcare Limited?
What is the P/E ratio of Sunil Healthcare Limited?
Is Sunil Healthcare Limited a good investment?
How can I buy Sunil Healthcare Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.